Reduced intensity chemotherapy with tyrosine kinase inhibitor and blinatumomab in a pediatric patient with Philadelphia chromosome-positive ALL and mechanical heart valves

Pediatr Blood Cancer. 2021 Jun;68(6):e28924. doi: 10.1002/pbc.28924. Epub 2021 Jan 28.

Authors

Richa Sharma¹, Clifford Takemoto², Benjamin Waller³, Ashley Holland¹, Ching-Hon Pui¹, Hiroto Inaba¹

Affiliations

¹ Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
² Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
³ Department of Cardiology, Le Bonheur Children's Hospital, Memphis, Tennessee, USA.

PMID: 33507612
DOI: 10.1002/pbc.28924

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Bispecific*
Child
Heart Valves
Humans
Philadelphia Chromosome*
Protein Kinase Inhibitors / adverse effects

Substances

Antibodies, Bispecific
Protein Kinase Inhibitors
blinatumomab